| Drug General Information |
| Drug ID |
D0MJ2H
|
| Former ID |
DIB012531
|
| Drug Name |
KD-7040
|
| Indication |
Pain [ICD9: 338, 356.0, 356.8,780; ICD10:G64, G90.0, R52, G89]
|
Phase 2 |
[1]
|
|---|
| Company |
Kalypsys Inc
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Target and Pathway |
| Target(s) |
Nitric oxide synthase, inducible |
Target Info |
Inhibitor |
[2]
|
|---|
|
BioCyc Pathway
|
Citrulline-nitric oxide cycle
|
|
KEGG Pathway
|
Arginine biosynthesis
|
|
Arginine and proline metabolism
|
|
Metabolic pathways
|
|
Calcium signaling pathway
|
|
HIF-1 signaling pathway
|
|
Peroxisome
|
|
Salmonella infection
|
|
Pertussis
|
|
Leishmaniasis
|
|
Chagas disease (American trypanosomiasis)
|
|
Toxoplasmosis
|
|
Amoebiasis
|
|
Tuberculosis
|
|
Pathways in cancer
|
|
Small cell lung cancer
|
|
NetPath Pathway
|
IL1 Signaling Pathway
|
|
IL2 Signaling Pathway
|
|
Pathway Interaction Database
|
IL12-mediated signaling events
|
|
Alpha9 beta1 integrin signaling events
|
|
ATF-2 transcription factor network
|
|
IL23-mediated signaling events
|
|
Signaling mediated by p38-alpha and p38-beta
|
|
HIF-1-alpha transcription factor network
|
|
Reactome
|
ROS production in response to bacteria
|
|
Nitric oxide stimulates guanylate cyclase
|
|
WikiPathways
|
Type II interferon signaling (IFNG)
|
|
Spinal Cord Injury
|
|
AGE/RAGE pathway
|
|
Effects of Nitric Oxide
|
| References |
| REF 1 | ClinicalTrials.gov (NCT00576108) A 2 Week Study of Topical KD7040 in the Treatment of Postherpetic Neuralgia (PHN). U.S. National Institutes of Health. |
|---|
| REF 2 | WO patent application no. 2014,0214,08, Method for treating cancer by anticancer agent co-administration. |
|---|
